Document is current

Any future updates will be listed below

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

Crossref DOI link: https://doi.org/10.1007/s00262-017-2091-y

Published Online: 2017-11-09

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark